Table 3.

Logistic Regression Assessing Pretreatment Predictors of Developing a Relapse or ≥2 New/Enlarging T2 Lesions in the First 12 Months of Injectable First-Line Therapy in Patients ≥11 Years Who Had an sNfL ≤3 Months Before Treatment Initiation

	Univariable			Multivariable model
	Odds ratio (95% CI)	p Value	N	Odds ratio (95% CI)	p Value	N
Relapse						82
Gd+ lesions >1a	2.75 (1.14–6.65)	0.025	88	2.07 (0.73–5.85)	0.172
T2 lesions >9b	1.30 (0.50–3.37)	0.589	91	0.65 (0.22–1.93)	0.433
sNfL >12.5 pg/mL	2.63 (1.11–6.19)	0.027	107	1.79 (0.58–5.56)	0.313
sNfL <7.5 pg/mL	0.28 (0.09–0.86)	0.026	107
≥2 new T2 lesions						76
Recent Gd+ lesions >1a	4.81 (1.82–12.71)	0.002	82	2.50 (0.81–7.73)	0.112
T2 lesions >9b	1.51 (0.50–4.54)	0.467	80	0.57 (0.15–2.22)	0.421
sNfL >12.5 pg/mL	4.44 (1.73–11.37)	0.002	91	5.02 (1.50–16.83)	0.009
sNfL <7.5 pg/mL	0.22 (0.07–0.66)	0.007	91

Abbreviations: Gd+ = gadolinium-enhancing; sNfL = serum neurofilament light chain.

^a≤30 days before NfL sampling.

^b≤6 months before NfL sampling.